Latest news with #NeerajSharma
Reuters
an hour ago
- Business
- Reuters
India's OneSource eyes weight-loss drug boost to order book
June 12 (Reuters) - Indian contract drug manufacturer OneSource Specialty Pharma ( opens new tab expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk ( opens new tab and U.S.-based Eli Lilly (LLY.N), opens new tab. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma ( opens new tab and Divi's ( opens new tab in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science ( opens new tab and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S.
Yahoo
an hour ago
- Business
- Yahoo
India's OneSource eyes weight-loss drug boost to order book
By Rishika Sadam (Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma and Divi's in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
a day ago
- Business
- Business Standard
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.
Business Standard
2 days ago
- Business
- Business Standard
OneSource Specialty jumps as Bangalore facility passes USFDA check
OneSource Specialty Pharma rose 3.98% to Rs 2,006 after the company announced that its flagship drug-device combination facility in Bangalore has retained its compliance status with the U.S. Food and Drug Administration (USFDA). The facility received a "Voluntary Action Indicated" (VAI) classification from the USFDA, following an inspection conducted between March 20 and March 28, 2025. During the inspection, the agency issued a Form 483 with four observations. However, after reviewing the company's comprehensive response and commitments, the agency has officially closed the inspection. Neeraj Sharma, managing director & CEO, said "The successful closure of our latest USFDA inspection is a pivotal moment in our journey, and we are very pleased with this outcome demonstrating our exemplary compliance status. Our flagship facility, Unit 2, is the cornerstone of our manufacturing capabilities in Drug Device Combinations (DDC), biologics drug substances, and complex injectables. This milestone validates our deep-rooted commitment to quality and is crucial as our partners prepare to launch key GLP-1 products in late FY26. We are excited to advance into our next significant commercial phase." OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.
Time of India
02-06-2025
- Politics
- Time of India
Punjab and Haryana high court declines to direct Punjab to appoint spy's son as Sub-Inspector, cites lack of policy
Chandigarh: The Punjab and Haryana high court has declined to direct Punjab to appoint a man as a sub-inspector (S-I) in the state police despite his father serving as an undercover agent and enduring a decade in a Pakistan prison following his capture for espionage. The court noted that in the absence of an established policy providing such appointments, it was not in a position to compel the state to act. Justice Jagmohan Bansal has passed the orders while dismissing a plea filed by Neeraj Sharma seeking directions to set aside the order dated Feb 7, 2024, and other orders of different dates whereby the Punjab govt rejected his representations for appointment as S-I in the state police. The petitioner claimed that his father, a spy with the Intelligence Bureau (IB), was apprehended by the Pakistan Army in Dec 1968. He was tried by a military court and awarded a sentence of 10 years. He was released in Dec 1974 and returned to India via the Wagah-Attari border, Amritsar. Through an application dated Aug 6, 2008, he requested then chief minister to help him like Kashmir Singh, a Hoshiarpur resident who was jailed for nearly 35 years in Pakistan on charges of spying and released in March 2008. Ferozepur deputy commissioner (DC), in a letter dated Nov 27, 2013, intimated that the monthly income of the family was around Rs 6,000 and they had only one house measuring 3 Marla. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Soluções de energia de confiança para Data Centers de IA Siemens Energy Learn More Undo On Dec 24, 2014, the CM sanctioned financial assistance of Rs 50,000. The petitioner submitted an application dated July 7, 2018, to the CM to give him a job like similarly situated persons. His father died on Oct 22, 2018. A communication took place between different authorities and ultimately, the petitioner, despite possessing qualifications of DPharmacy and BSc (medical), was offered the post of constable, which he took up. However, his pleas for appointment to the higher post of S-I were rejected. In his plea before the HC, his counsel submitted that the petitioner is a highly qualified person, and the state has offered Class-B posts to similarly situated persons. On the grounds of parity, the petitioner should be given the post of at least assistant sub-inspector instead of constable. Responding to the plea, the Punjab govt submitted that there is no policy of the state to make appointments as claimed by the petitioner. After hearing all the parties, the bench observed that the court, in the absence of an express or implied policy of the state govt, cannot direct authorities to consider the petitioner for a higher rank, especially when he has already been offered and appointed as a constable without complying with the terms and conditions applicable to the post. MSID:: 121570821 413 |
